Aficamten is an investigational cardiac myosin inhibitor for the potential treatment of patients with hypertrophic cardiomyopathy (HCM disease).
Omecamtiv mecarbil is a selective small molecule cardiac myosin activator. Omecamtiv mecarbil is designed to directly target the contractile mechanism, or pumping function of the heart. By stimulating cardiac myosin, a protein responsible for converting chemical energy into the mechanical force that helps the heart contract, omecamtiv mecarbil may improve cardiac muscle performance. Preclinical research has shown that cardiac myosin activators increase cardiac contractility without affecting intracellular myocyte calcium concentrations or myocardial oxygen consumption.
Omecamtiv mecarbil was the subject of a comprehensive clinical trials program comprised of more than 30 clinical trials, including the pivotal Phase 3 clinical trial of over 8,000 patients with heart failure with reduced ejection fraction.